Results 11 to 20 of about 265,496 (312)

A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation

Haematologica, 2016
Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén, Olle Ringdén, Karin Garming-Legert, Per Ljungman, Jacek Winiarski, Kari Remes, Maija Itälä-Remes, Mats Remberger, Jonas Mattsson   +8 more
doaj   +1 more source

Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Journal of Immunology Research, 2016
Background. Graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). We designed a functional assay for assessment of individual risk for acute GVHD. Study Design and Methods.
Darius Sairafi, Arwen Stikvoort, Jens Gertow, Jonas Mattsson, Michael Uhlin   +4 more
doaj   +1 more source

Allogeneic Stem Cells Alter Gene Expression and Improve Healing of Distal Limb Wounds in Horses. [PDF]

, 2017
Distal extremity wounds are a significant clinical problem in horses and humans and may benefit from mesenchymal stem cell (MSC) therapy. This study evaluated the effects of direct wound treatment with allogeneic stem cells, in terms of gross, histologic,
Aristizobal, Fabio A, Bledsoe, Andrea, Bohannon-Worsley, Laurie K, Borjesson, Dori L, Clark, Kaitlin C, Davidyan, Arik, Gray, Sarah N, Kol, Amir, LeJeune, Sarah S, Textor, Jamie A, Walker, Naomi J, Woolard, Kevin D   +11 more
core   +1 more source

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

Frontiers in Immunology, 2023
IntroductionCOVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients.MethodsThis study reports on 986 patients reported to the EBMT registry during the first 29 months of the ...
Per Ljungman, Per Ljungman, Gloria Tridello, Jose Luis Piñana, Jose Luis Piñana, Fabio Ciceri, Henrik Sengeloev, Alexander Kulagin, Stephan Mielke, Stephan Mielke, Zeynep Arzu Yegin, Matthew Collin, Sigrun Einardottir, Sigrun Einardottir, Sophie Ducastelle Lepretre, Johan Maertens, Antonio Campos, Elisabetta Metafuni, Herbert Pichler, Frantisek Folber, Frantisek Folber, Carlos Solano, Emma Nicholson, Meltem Kurt Yüksel, Kristina Carlson, Beatriz Aguado, Caroline Besley, Jenny Byrne, Immaculada Heras, Fiona Dignan, Nicolaus Kröger, Christine Robin, Anjum Khan, Stig Lenhoff, Anna Grassi, Veronika Dobsinska, Nuno Miranda, Maria-Jose Jimenez, Ipek Yonal-Hindilerden, Keith Wilson, Dina Averbuch, Simone Cesaro, Alienor Xhaard, Nina Knelange, Jan Styczynski, Malgorzata Mikulska, Rafael de la Camara   +46 more
doaj   +1 more source

Intra-operative blood salvage in total hip and knee arthroplasty [PDF]

, 2016
Purpose To review records of 371 patients who underwent total hip or knee arthroplasty (THA or TKA) with intra-operative blood salvage to determine the allogeneic blood transfusion rate and the predictors for allogeneic blood transfusion. Methods Records
Beller, Elaine, Dan, Michael, Liu, David, Martos, Sara Martinez   +3 more
core   +1 more source

IFNγ, and to a Lesser Extent TNFα, Provokes a Sustained Endothelial Costimulatory Phenotype

Frontiers in Immunology, 2021
BackgroundVascular endothelial cells (EC) are critical for regulation of local immune responses, through coordination of leukocyte recruitment from the blood and egress into the tissue.
Nicole M. Valenzuela
doaj   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

CNS Oncology, 2018
Aim: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine – composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors.
Daniela A Bota, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank PK Hsu, Axel H Schönthal, Florence M Hofman, Thomas C Chen, Raphael Zidovetzki, Chrystel Pretto, Ankie Strik, Virgil EJC Schijns, Apostolos Stathopoulos   +14 more
doaj   +1 more source

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Oncology, 2020
Relapse is the main cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Ahmad I. Antar, Ahmad I. Antar, Zaher K. Otrock, Iman Abou Dalle, Jean El-Cheikh, Ali Bazarbachi   +5 more
doaj   +1 more source

Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes

Frontiers in Veterinary Science, 2021
Despite significant immunosuppressive activity, allogeneic mesenchymal stromal cells (MSCs) carry an inherent risk of immune rejection when transferred into a recipient.
J. Lacy Kamm, Christopher B. Riley, Natalie Parlane, Erica K Gee, C. Wayne McIlwraith   +4 more
doaj   +1 more source